Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

A Study to Investigate the Efficacy and Safety of Dato-DXd-based Combinations in Participants With TROP2 NMR+ NSCLC (PATAGONIA)

10 novembre 2026 mis à jour par: AstraZeneca

A Global, Multicentre, Phase II Platform Study of Datopotamab Deruxtecan (Dato-DXd)-Based Combinations in Adult Participants With TROP2 NMR-positive Non-small Cell Lung Cancer (NSCLC) (PATAGONIA)

Phase II, open-label, multicentre, multi-cohort platform study to determine the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd)-based combinations for the treatment of TROP2 NMR+ NSCLC.

Aperçu de l'étude

Description détaillée

This is a Phase II, open-label, multicentre, multi-cohort platform study to determine the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd)-based combinations for the treatment of TROP2 NMR+ NSCLC.

This study is designed as non-comparative.

Participants will be randomised to Treatment A or B.

In the module 1 of this study, Dato-DXd-based regimens will be assessed in participants with non-AGA NSCLC whose tumours have been prospectively identified as TROP2 NMR+.

The proposed primary objectives are to assess the efficacy of Dato-DXd combined with durvalumab and carboplatin and Dato-DXd combined with durvalumab in terms of PFS per RECIST 1.1 as assessed by the investigator.

Participants in both treatment groups will receive study treatment medicines until investigator-assessed radiological progression per RECIST 1.1, unacceptable toxicity, withdrawal of consent, or an intervention discontinuation criterion is met. There is no maximum limit to the number of cycles of Dato-DXd and/or durvalumab that a participant in either treatment group can receive. The maximum treatment for carboplatin is 4 cycles.

The study will be conducted in several countries worldwide.

Type d'étude

Interventionnel

Inscription (Estimé)

250

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

      • Ciudad Autonoma Buenos Aires, Argentine, 1405
        • Research Site
      • Ciudad de Buenos Aires, Argentine, C1427ARO
        • Research Site
      • La Rioja, Argentine, 5300
        • Research Site
      • Rosario, Argentine, 2000
        • Research Site
      • Rosario, Argentine, S2000KZE
        • Research Site
      • San Juan, Argentine, 5400
        • Research Site
      • Viedma, Argentine, R8500ACE
        • Research Site
      • Adelaide, Australie, 5000
        • Research Site
      • Bedford Park, Australie, 5042
        • Research Site
      • Southport, Australie, 4215
        • Research Site
      • Waratah, Australie, 2298
        • Research Site
      • Woodville, Australie, 5011
        • Research Site
      • Blumenau, Brésil, 89010-340
        • Research Site
      • Curitiba, Brésil, 80810-050
        • Research Site
      • Ijuí, Brésil, 98700-000
        • Research Site
      • Porto Alegre, Brésil, 90610-000
        • Research Site
      • Porto Alegre, Brésil, 91350200
        • Research Site
      • Rio de Janeiro, Brésil, 22281-100
        • Research Site
      • Salvador, Brésil, 40170-110
        • Research Site
      • Santa Maria, Brésil, 97015-450
        • Research Site
      • São Paulo, Brésil, 01246-000
        • Research Site
      • São Paulo, Brésil, 01509-900
        • Research Site
      • São Paulo, Brésil, 03102-006
        • Research Site
      • Teresina, Brésil, 64049-200
        • Research Site
      • Vitória, Brésil, 29043-260
        • Research Site
    • Alberta
      • Edmonton, Alberta, Canada, T6G 1Z2
        • Research Site
    • Ontario
      • Brampton, Ontario, Canada, L6R 3J7
        • Research Site
      • Toronto, Ontario, Canada, M4N 3M5
        • Research Site
    • Quebec
      • Montreal, Quebec, Canada, H3T 1M5
        • Research Site
      • Beijing, Chine, 100730
        • Research Site
      • Beijing, Chine, 100191
        • Research Site
      • Changchun, Chine, 130021
        • Research Site
      • Changsha, Chine, 410013
        • Research Site
      • Chengdu, Chine, 610041
        • Research Site
      • Chongqing, Chine, 400030
        • Research Site
      • Guangzhou, Chine, 510000
        • Research Site
      • Hangzhou, Chine, 310009
        • Research Site
      • Harbin, Chine, 150081
        • Research Site
      • Nanchang, Chine, 330000
        • Research Site
      • Nanning, Chine, 530021
        • Research Site
      • Shandong, Chine
        • Research Site
      • Shanghai, Chine, 200032
        • Research Site
      • Shanghai, Chine, 200030
        • Research Site
      • Tianjin, Chine, 300051
        • Research Site
      • Wuhan, Chine, 430022
        • Research Site
      • Yangzhou, Chine, 225001
        • Research Site
      • Zhengzhou, Chine, 450008
        • Research Site
      • Zhengzhou, Chine, 450000
        • Research Site
      • Cheongju-si, Corée du Sud, 28644
        • Research Site
      • Jinju, Corée du Sud, 660-702
        • Research Site
      • Seongnam-si, Corée du Sud, 13620
        • Research Site
      • Seoul, Corée du Sud, 5505
        • Research Site
      • Seoul, Corée du Sud, 120-749
        • Research Site
      • Suwon, Corée du Sud, 16247
        • Research Site
      • Marseille, France, 13273
        • Research Site
      • Nice, France, 06000
        • Research Site
      • Paris, France, 75014
        • Research Site
      • Paris, France, 75005
        • Research Site
      • Pessac, France, 33604
        • Research Site
      • Villefranche-sur-Saône, France, 69655
        • Research Site
      • Lucca, Italie, 55100
        • Research Site
      • Orbassano, Italie, 10043
        • Research Site
      • Parma, Italie
        • Research Site
      • Rozzano, Italie, 20089
        • Research Site
      • Torrette, Italie, 60126
        • Research Site
      • Verona, Italie, 37126
        • Research Site
      • Lodz, Pologne, 93-338
        • Research Site
      • Lodz, Pologne, 93-513
        • Research Site
      • Przemyśl, Pologne, 37-700
        • Research Site
      • Warsaw, Pologne, 00-124
        • Research Site
      • Singapore, Singapour, 119228
        • Research Site
      • Singapore, Singapour, 308433
        • Research Site
      • Singapore, Singapour, 217562
        • Research Site
      • Singapore, Singapour, 168583
        • Research Site
    • California
      • Irvine, California, États-Unis, 92618
        • Research Site
      • Oakland, California, États-Unis, 94612
        • Research Site
    • Colorado
      • Golden, Colorado, États-Unis, 80401
        • Research Site
    • Connecticut
      • New Haven, Connecticut, États-Unis, 06519
        • Research Site
    • Florida
      • Miami, Florida, États-Unis, 33170
        • Research Site
      • Tampa, Florida, États-Unis, 33612
        • Research Site
    • Georgia
      • Atlanta, Georgia, États-Unis, 30318
        • Research Site
    • Illinois
      • Peoria, Illinois, États-Unis, 61637
        • Research Site
    • South Carolina
      • Greer, South Carolina, États-Unis, 29651
        • Research Site
      • Greer, South Carolina, États-Unis, 29650
        • Research Site
    • Texas
      • Sugar Land, Texas, États-Unis, 77479
        • Research Site
    • Utah
      • Salt Lake City, Utah, États-Unis, 84112
        • Research Site
    • West Virginia
      • Morgantown, West Virginia, États-Unis, 26506
        • Research Site

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

INCLUSION CRITERIA:

  1. Participant must be ≥ 18 years of age at the time of signing the ICF.

  2. Pathologically documented NSCLC that:

    1. Has documented non-squamous histology
    2. Is TROP2 NMR positive
    3. Documented lack of sensitising EGFR mutation, as well as ALK and ROS1 rearrangements on tumour tissue.
  3. Stage IIIB or IIIC disease not amenable to surgical resection or definitive chemoradiation, or Stage IV metastatic NSCLC at the time of randomisation, as per the American Joint Committee on Cancer Staging System, 9th Edition.

  4. The ECOG PS of 0 to 2.

  5. Known tumour PD-L1 status.

  6. Minimum life expectancy of 12 weeks.

  7. Provision of acceptable FFPE tumour sample from a lesion not previously irradiated.

  8. At least 1 lesion, not previously irradiated, that qualifies as a RECIST 1.1 target lesion at baseline.

  9. Adequate bone marrow reserve and organ function.

  10. Contraceptive use by participants or participant partners.

  11. Capable of giving signed informed consent.

  12. Provision of signed and dated optional informed consent.

EXCLUSION CRITERIA:

  1. As judged by the investigator, any evidence of diseases, chronic diverticulitis or previous complicated diverticulitis, or history of allogenic organ transplant, which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardise compliance with the protocol.

  2. History of another primary malignancy except for malignancy treated with curative intent with no known active disease within 3 years before the first dose of study intervention and of low potential risk for recurrence, adequately resected basal cell carcinoma of the skin or squamous cell carcinoma of the skin, lentigo maligna that has undergone potentially curative therapy, or adequately treated in situ disease without evidence of disease.

  3. Squamous histology or mixed SCLC and NSCLC, or sarcomatoid variant of NSCLC, or lung neuroendocrine tumours .

  4. Has documented tumour genomic alterations in EGFR, ALK, ROS1, NTRK, BRAF V600E, RET, MET exon 14, or any other actionable driver oncogenes for which there are locally approved and available targeted first-line therapies.

    Note: Participants whose tumours harbour KRAS mutations are eligible for the study

  5. Persistent toxicities caused by previous anti-cancer therapy, excluding alopecia or vitiligo, not yet improved to Grade ≤ 1 or baseline.

  6. Active or prior documented autoimmune, connective tissue or inflammatory disorders, autoimmune pneumonitis, or autoimmune myocarditis.

  7. Spinal cord compression or CNS metastases, unless asymptomatic, stable, and not requiring treatment with corticosteroids or anticonvulsants for at least 7 days prior to randomisation.

  8. History of leptomeningeal carcinomatosis or metastasis.

  9. Clinically significant corneal disease.

  10. Has active or uncontrolled HBV or HCV infection.

  11. Known HIV infection that is not well controlled.

  12. Uncontrolled infection requiring systemic antibiotics, antivirals, or antifungals, suspected infections or inability to rule out infections.

  13. Known to have active tuberculosis infection.

  14. Mean resting QTcF > 470 ms, regardless of gender, obtained from triplicate 12-lead ECGs performed at screening.

  15. Uncontrolled or significant cardiac disease.

  16. History of ILD/pneumonitis.

  17. Has clinically severe pulmonary function compromised.

  18. Prior exposure to:

    1. Any agent, including ADC, containing a chemotherapeutic agent targeting topoisomerase I
    2. Chemotherapy or any other systemic therapy for first-line Stage IIIB, IIIC, or IV NSCLC
    3. TROP2-targeted therapy
    4. Chloroquine/hydroxychloroquine without an adequate treatment washout period.
  19. Participants who have received any prior adjuvant, neoadjuvant, or definitive chemoradiation for early stage disease (Stage I to III) are eligible, provided they meet the protocol-defined conditions.

  20. Current or prior use of immunosuppressive medication within 14 days before the first dose of study intervention.

  21. Any concurrent anti-cancer treatment.

  22. Any concomitant medication known to be associated with Torsades de Pointes.

  23. Receipt of live, attenuated vaccine within 30 days prior to the first dose of study intervention.

  24. Received prior radiotherapy to the brain within 2 weeks of start of study intervention or received palliative radiotherapy to the chest within 4 weeks of start of study intervention or has ongoing radiation-related toxicities requiring corticosteroids.

  25. Major surgical procedure or significant traumatic injury within ≤ 4 weeks of the first dose of study intervention or an anticipated need for major surgery during the study.

  26. Participation in another clinical study with a study intervention or investigational medicinal device administered in the last 4 weeks prior to randomisation or concurrent participation in another clinical study.

  27. Participants with a known history of severe hypersensitivity reactions to study intervention or any excipients of these products.

  28. Participants with a known history of severe hypersensitivity reactions to other monoclonal antibodies.

  29. Allocation to a stratum that has reached the cap.

  30. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).

  31. Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.

  32. For females only: Is pregnant (confirmed with positive serum pregnancy test), or breastfeeding, or planning to become pregnant.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Treatment A

Participants will receive Dato-DXd and durvalumab Q3W on Day 1 of every 21-day cycle.

Treatment A/B: Dato-DXd as IV infusion.

Autres noms:
  • Datopotamab Deruxtecan

Treatment A/B: Durvalumab as IV infusion

Expérimental: Treatment B

Participants will receive Dato-DXd, durvalumab, and carboplatin Q3W on Day 1 of every 21-day cycle for the first 4 cycles, followed by Dato-Dxd and durvalumab Q3W

Treatment A/B: Dato-DXd as IV infusion.

Autres noms:
  • Datopotamab Deruxtecan

Treatment A/B: Durvalumab as IV infusion

Treatment B: Carboplatin as IV infusion

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
PFS as assessed by investigator on Treatment A
Délai: Date of first dose of study intervention until disease progression per RECIST 1.1 or death from any cause, or end of study whichever occurs first, up to approximately 30 months

PFS is defined as time from date of first dose of any study treatment until progression per RECIST 1.1 as assessed by the investigator at the local site or death due to any cause.

Primary measure of interest is the median PFS.

Date of first dose of study intervention until disease progression per RECIST 1.1 or death from any cause, or end of study whichever occurs first, up to approximately 30 months
PFS as assessed by investigator on Treatment B
Délai: Date of first dose of study intervention until disease progression per RECIST 1.1 or death from any cause, or end of study whichever occurs first, up to approximately 30 months

PFS is defined as time from date of first dose of any study treatment until progression per RECIST 1.1 as assessed by the investigator at the local site or death due to any cause.

Primary measure of interest is the median PFS.

Date of first dose of study intervention until disease progression per RECIST 1.1 or death from any cause, or end of study whichever occurs first, up to approximately 30 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Objective Response rate (ORR) in each treatment arm
Délai: Date of first dose of study intervention until disease progression per RECIST 1.1 or death from any cause, or end of study whichever occurs first, up to approximately 30 months

ORR is defined as the proportion of participants who have a confirmed response (CR or PR), as determined by the investigator at local site per RECIST 1.1.

For each study treatment group, the primary measure of interest is the estimate of ORR.

Date of first dose of study intervention until disease progression per RECIST 1.1 or death from any cause, or end of study whichever occurs first, up to approximately 30 months
Duration of response (DoR) in each treatment arm
Délai: Date of first dose of study intervention until disease progression per RECIST 1.1 or death from any cause, or end of study whichever occurs first, up to approximately 30 months

DoR is defined as the time from the date of first documented confirmed response until the date of documented progression per RECIST 1.1 as assessed by the investigator at the local site or death due to any cause.

For each study treatment group, the primary measure of interest is the median DoR.

Date of first dose of study intervention until disease progression per RECIST 1.1 or death from any cause, or end of study whichever occurs first, up to approximately 30 months

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Safety as measured by the number of patients with at least one adverse event (AE), by study treatment
Délai: Date of first dose of study intervention until earliest of 90 days after study treatment discontinuation, death or end of study, up to approximately 30 months

Proportion of patients with at least one AE

Date of first dose of study intervention until earliest of 90 days after study treatment discontinuation, death or end of study, up to approximately 30 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

30 novembre 2026

Achèvement primaire (Estimé)

16 décembre 2028

Achèvement de l'étude (Estimé)

22 décembre 2028

Dates d'inscription aux études

Première soumission

3 septembre 2026

Première soumission répondant aux critères de contrôle qualité

10 novembre 2026

Première publication (Réel)

17 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

17 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

10 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared

Délai de partage IPD

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Critères d'accès au partage IPD

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • SÈVE

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner